Dr. Reddy's Laboratories shares climbed 3.8% as the market focused on sequential recovery rather than a 36% year-on-year profit decline to ₹925 crore. While lower lenalidomide sales in North America hurt quarterly results, brokerages upgraded the stock, banking on upcoming growth from the Abatacept biosimilar and the Qdenga vaccine.
Dr. Reddy's Laboratories saw its share price jump 3.8% on the National Stock Exchange on Monday, despite the pharmaceutical firm reporting a 36% drop in consolidated net profit for the second quarter of fiscal 2027. The company's profit stood at ₹925 crore, while revenue dipped 0.5% to ₹8,670.8 crore compared to the same period last year. The decline was largely driven by softening sales of its generic drug, lenalidomide, in the competitive North American market.
Investors appeared to overlook the yearly profit decline, choosing instead to focus on the company's sequential performance. On a quarter-on-quarter basis, the company showed significant improvement, with profit jumping 109% and revenue increasing by 7.4%. This recovery suggests that the business is stabilizing after the previous quarter’s challenges. Management also managed to keep gross margins steady at 52.1%, which aligns with their existing target range of 50% to 55%.
Brokerage Outlook and Growth Catalysts
Following the earnings announcement, multiple brokerages upgraded their ratings on the stock, signaling confidence in the company's future growth strategy. Systematix Institutional Research moved the stock to a 'Buy' rating with a target price of ₹1,461, while Elara Securities upgraded its stance to 'Accumulate' with a target of ₹1,338. These analysts highlighted that the current dip in revenue is likely temporary.
The primary optimism stems from the company's product pipeline, specifically the upcoming launch of the Abatacept biosimilar and the rollout of the Qdenga dengue vaccine. Analysts expect these products to begin contributing to earnings by fiscal year 2028, potentially offsetting the pressure from the North American generics segment. Choice Institutional Equities maintained an 'Add' rating with a target price of ₹1,380, while noting that investors should still watch for the sustainability of current operating margins.
Risks and Monitorables
While the outlook is positive, the company still faces potential challenges. Success in the next fiscal year depends heavily on the timely execution of its new product launches and regulatory approvals. Furthermore, the North American generic drug market remains highly competitive, which could continue to pressure pricing and margins. Investors should monitor whether the company can maintain its current margin guidance as it ramps up spending for these major product launches. The speed at which Abatacept and Qdenga contribute to the top line will be key for shareholders in the coming quarters.